TIRZEPATIDE 30mg

Product Overview

Tirzepatide 30mg is a synthetic dual incretin receptor agonist consisting of 39 amino acids designed to interact with both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor pathways in experimental systems.

Peptides are short chains of amino acids that act as signaling molecules within biological systems. In laboratory environments researchers study peptide molecules to better understand receptor activation pathways, intracellular signaling, and regulatory mechanisms involved in cellular communication.

Tirzepatide 30mg has become a molecule of interest in peptide research because structural modifications support receptor interaction across multiple incretin pathways while maintaining molecular stability during investigation.

Chemical Information

Peptide Name: Tirzepatide 30mg
Quantity: 30mg
Sequence Length: 39 amino acids
Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight: ~4813.5 g/mol
Purity: ≥99%
Appearance: Lyophilized white powder

Analytical Verification

Each batch of tirzepatide 30mg undergoes analytical verification to confirm compound identity and purity. Analytical procedures commonly include high-performance liquid chromatography (HPLC) and additional analytical techniques used to evaluate peptide composition.

Verification procedures evaluate:

• peptide purity profile
• chromatographic retention time
• batch consistency
• molecular identity confirmation

Analytical data corresponding to each batch is documented through a Certificate of Analysis (COA).

Certificate of Analysis

A Certificate of Analysis provides documentation associated with a specific production lot. These documents typically contain analytical data confirming compound purity and laboratory testing methodology.

COA documentation commonly includes:

• batch identification number
• purity percentage
• chromatographic testing results
• analytical method
• laboratory verification data

Researchers reference COA documentation to maintain traceability and consistency within experimental workflows.

Peptide Synthesis

Tirzepatide 30mg is produced using solid-phase peptide synthesis (SPPS), a process widely used for assembling complex peptide sequences through sequential amino acid coupling.

The synthesis process typically includes:

sequential amino acid assembly

purification using chromatographic separation

analytical confirmation of molecular identity

lyophilization to maintain compound stability

Following purification, the compound is freeze-dried to preserve structural integrity during storage and transportation.

Storage Conditions

Lyophilized peptides should be stored under controlled conditions to maintain stability.

Recommended handling considerations include:

• storing in a cool dry environment
• minimizing exposure to moisture and heat
• avoiding repeated freeze-thaw cycles after reconstitution

Proper storage helps maintain compound integrity during laboratory research.

Available Sizes

Tirzepatide is available in multiple vial sizes:

Tirzepatide – 15mg

Tirzepatide – 10mg

Related Peptide Compounds

Researchers examining incretin signaling pathways often investigate other peptide analogues within the same molecular class.

Related compounds include:

Tirzepatide – 10mg
Tirzepatide – 30mg
Semaglutide – 10mg
Retatrutide – 10mg

References

Scientific literature describing peptide signaling and incretin receptor interactions is available through peer-reviewed research databases.

PubMed

Disclaimer

This product is supplied strictly as a laboratory reference material.

Not for human or animal consumption.

Products distributed by Aevitas Research are intended exclusively for laboratory research purposes and must be handled by qualified professionals in controlled research environments.

By purchasing this material, the buyer acknowledges that it will be used in accordance with applicable regulations governing laboratory research products.